SEC Form 4 · accession 0001209191-16-142355
Sarepta Therapeutics, Inc. · SRPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David T Howton
Officer — SVP, General Counsel
Period of report
Sep 19, 2016
Accepted (ET)
Sep 21, 2016 · 9:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000873303
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 19, 2016 | M | 8,000 | $13.90 | A | 11,168 | D | |
| Common StockF1 | Sep 19, 2016 | S | 8,000 | $50.00 | D | 3,168 | D | |
| Common StockF2 | Sep 19, 2016 | A | 464 | $0.00 | A | 3,632 | D | |
| Common StockF3 | Sep 19, 2016 | A | 19,125 | $0.00 | A | 22,757 | D | |
| Common StockF1 | Sep 19, 2016 | S | 1,304 | $50.00 | D | 21,453 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Options (right to buy)F1 | $13.90 | Sep 19, 2016 | M | 8,000 | D | Feb 27, 2016 | Feb 27, 2025 | Common Stock | 8,000 | 72,007 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction.
- F2100% of the Restricted Stock Award ("RSA") granted on September 19, 2016 vests six months from the date of grant. The Company will withhold the shares to satisfy the executive's tax obligation upon vesting.
- F315,300 RSAs vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, with an additional 3,825 RSAs vesting during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million. The Company will withhold the shares to satisfy the executive's tax obligation upon vesting.